A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis : A Phase 2/3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
This trial will have 3 parts plus screening and follow-up parts:Parts A and B: Participants will either be included in part A or B. Each is a 24-week double-blind (this means none of the participants, doctors, or other trial staff will know what treatment each participant took) part where participants will receive either dupilumab or a placebo (a placebo looks like a trial drug but does not have any medicine in it).Part C: 28-week extension part that will include participants from parts A and B and all participants will receive dupilumab.
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
ClinicalTrials.gov - (2024) vom: 12. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: April 26, 2023, Last downloaded: ClinicalTrials.gov processed this data on April 17, 2024, Last updated: April 17, 2024 |
|---|
| Study ID: |
NCT05831176 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG009160248 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG009160248 | ||
| 003 | DE-627 | ||
| 005 | 20240417010447.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230503s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG009160248 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT05831176 | ||
| 035 | |a (UBBS_Klinische_Studien)R668-EGE-2213 | ||
| 035 | |a (UBBS_Klinische_Studien)2022-500795-62-00 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis |b A Phase 2/3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: April 26, 2023, Last downloaded: ClinicalTrials.gov processed this data on April 17, 2024, Last updated: April 17, 2024 | ||
| 520 | |a This trial will have 3 parts plus screening and follow-up parts:Parts A and B: Participants will either be included in part A or B. Each is a 24-week double-blind (this means none of the participants, doctors, or other trial staff will know what treatment each participant took) part where participants will receive either dupilumab or a placebo (a placebo looks like a trial drug but does not have any medicine in it).Part C: 28-week extension part that will include participants from parts A and B and all participants will receive dupilumab | ||
| 650 | 2 | |a Gastritis | |
| 650 | 2 | |a Gastrointestinal Diseases | |
| 650 | 2 | |a Digestive System Diseases | |
| 650 | 2 | |a Eosinophilic Esophagitis | |
| 650 | 2 | |a Enteritis | |
| 650 | 2 | |a Duodenitis | |
| 650 | 2 | |a Eosinophilia | |
| 650 | 4 | |a Study Type: Interventional | |
| 650 | 4 | |a Recruitment Status: Recruiting | |
| 650 | 4 | |a Phase: Phase 2, Phase 3 | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2024) vom: 12. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:12 |g month:04 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT05831176 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 12 |c 04 | ||